/C O R R E C T I O N — Musee Platinum Tokyo/

In the news release, “(Musée Platinum Tokyo Launches DUO Hydrogen Treatment Across All Salons in Singapore)”, issued on (December 18 2025) by Musée Platinum Tokyo over PR Newswire, we are advised by the company that all mentions of “Musée Platinum Tokyo” should read “Musee Platinum Tokyo” rather than “Musée Platinum Tokyo” as originally issued inadvertently. […]

BOE and UNESCO deepen cooperation in science to shape a sustainable future through foresight and action

BOE recently participated in two signature UNESCO events in Paris and Namibia, demonstrating its leading-edge concepts and ecosystem building capacity in global science governance and STEM education innovation. BOE is the first Chinese technology company to endorse the United Nations International Decade of Sciences for Sustainable Development, 2024-2033. https://mma.prnewswire.com/media/2412154/BOE_Logo.jpg Dialoguein Paris: contributing foresight on global

When East Meets West: Global Youth Sculpture Cyber Program Fosters Cultural Dialogue

A report fromJiangsunow. Watch video: https://www.youtube.com/watch?v=T8zn10Ke1xs&t=5s A unique digital art initiative is bridging ancient civilizations and engaging a new generation. Following the permanent installation of renowned Chinese sculptor Wu Weishan's work, Divine Encounter-Dialogue between Confucius and Socrates, at the foot of Athens' Acropolis in 2021, a new chapter in cultural exchange has begun. The “Sculpting

Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy

Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion protein in Cell Reports Medicine. The peer-reviewed article details the preclinical and translational validation of FP008 (anti-PD-1 × IL-10M). This first-in-class bifunctional fusion protein is designed to address a

Yahoo HK Best Brand Awards 2025 – Recognise Over 20 of Hong Kong’s Most Beloved Brands

Recognizing the Power of Brands That Truly Move Hongkongers Yahoo has announced the winners of theYahoo HK Best Brand Awards 2025, recognising over 20 brands that have built strong, lasting connections with Hong Kong consumers and demonstrated meaningful market influence amid an increasingly dynamic digital landscape. https://mma.prnewswire.com/media/2850825/Yahoo_HK_Best_Brand_Awards_2025_crowns_20_Hong_Kong_s.jpg The awards ceremony, held last week at Hyatt

Maison&Objet Intérieurs Hong Kong 2025 Successfully Concludes Second Edition

Delivering strong industry turnout, dynamic sales, and shoppable experiencesunder the theme “Crossroads” Maison&Objet Intérieurs Hong Kong returned to the Hong Kong Convention and Exhibition Centre from 3-6 December 2025, presenting an enhanced second edition under the theme “Crossroads.” The programme brought together three pillars – Inspiration (Design Factory), Discovery (Design Showcase), and Encounters (Le Club)

Muheel Selects MRI Software to Power Next-Generation Facilities Management Across the Kingdom

As the Facilities Management sector undergoes a rapid shift toward digital integration and data-driven service models, FM service providers are increasingly required not only to respond to operational demands but to anticipate them with precision. In line with this evolution, Muheel, one of Saudi Arabia's premier integrated facilities management providers, is leveraging MRI Software's global

S2 Capital Acquires Ovaltine Apartments, Marking Entry into the Chicago Market

S2 Capital (“S2”), a national vertically integrated real estate investment manager, today announced the acquisition of Ovaltine Apartments, a 344-unit garden and loft-style multifamily community located in Villa Park, Illinois, a western suburb of Chicago, marking the firm's first investment in the greater Chicago area. Terms of the transaction were not disclosed. https://mma.prnewswire.com/media/2850826/S2_Ovaltine_Apartments.jpg The acquisition

GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea

Phase 2 IND submission targeted for the second half of 2026- Demonstrating the competitiveness of GC Biopharma's mRNA platform GC Biopharma (006280.KS), a leading global biopharmaceutical company, announced today that Ministry of Food and Drug Safety (MFDS) in South Korea has approved the Investigational New Drug (IND) application for the Phase 1 clinical trial of

Scroll to Top